First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Slides:

Advertisements

Similar presentations

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Advertisements

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful.

Surgically Resected Isolated Hepatic Metastasis from Non-small Cell Lung Cancer: A Case Report Kyu-Sik Kim, Kook-Joo Na, Yun-Hyeon Kim, Sung-Ja Ahn,

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD, Jung-Il Lee,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Imaging Phenotyping Using Radiomics to Predict Micropapillary Pattern within Lung Adenocarcinoma So Hee Song, MD, Hyunjin Park, PhD, Geewon Lee, MD,

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Factors Associated With Depression in Disease-Free Stomach Cancer Survivors Kyung Hee Han, MD, PhD, In Cheol Hwang, MD, PhD, Sung Kim, MD, PhD, Jae-Moon.

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

George Blumenschein, MD, John V. Heymach, MD, PhD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation Bhumsuk.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer Yoichi Nakamura, MD, PhD, Kazumi Sano, PhD, Hiroshi.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Management of Ground-Glass Opacity Lesions Detected in Patients with Otherwise Operable Non-small Cell Lung Cancer Hong Kwan Kim, MD, Yong Soo Choi,

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Prognostic Differences in Subgroups of Patients With Surgically Resected T3 Non-Small Cell Lung Cancer Jae Hyun Jeon, MD, Moon Soo Kim, MD, Duk Hwan.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Non– Small-Cell Lung Cancer Seung Jun Lee, MD, Jinwoo Lee, MD, Young.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

High Frequency of Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine.

Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer Yoon Hee Choi, MD,

Analysis of Treatment Outcomes of Intraventricular Chemotherapy in 105 Patients for Leptomeningeal Carcinomatosis from Non–Small-Cell Lung Cancer Ho-Shin.

Marianna Koczywas, MD, Mihaela C. Cristea, MD

Metastatic Lung Cancer to the Pancreas

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

A Functional Polymorphism on Chromosome 15q25 Associated with Survival of Early Stage Non–Small-Cell Lung Cancer Guang Jin, MD, PhD, Eun Young Bae, BS,

David Garfield, MD Journal of Thoracic Oncology

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Farhood Farjah, MD, MPH, David R. Flum, MD, MPH, Scott D

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Sleeve Lobectomy as an Alternative Procedure to Pneumonectomy for Non-small Cell Lung Cancer Joon Suk Park, MD, Hee Chul Yang, MD, Hong Kwan Kim, MD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Mark A. Socinski, MD Journal of Thoracic Oncology

Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage.

Presentation transcript:

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD, Ji-Youn Han, MD, Tak Yun, MD, Geon Kook Lee, MD, Hyae Young Kim, MD, Ji-Hyun Sung, MS, Jin Soo Lee, MD Journal of Thoracic Oncology Volume 5, Issue 3, Pages 361-368 (March 2010) DOI: 10.1097/JTO.0b013e3181cee1ea Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Patient collection. Journal of Thoracic Oncology 2010 5, 361-368DOI: (10.1097/JTO.0b013e3181cee1ea) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Radiologic response to gefitinib in patients with advanced non-small cell lung cancer (NSCLC) with a poor performance status (PS) of Eastern Cooperative Oncology Group (ECOG) 3 or 4. A, Case 1: chest x-ray scans (top) and computed tomography scans of the chest (bottom). B, Case 2: positron emission tomography scans (top) and magnetic resonance images of brain (bottom), before and after gefitinib treatment. Journal of Thoracic Oncology 2010 5, 361-368DOI: (10.1097/JTO.0b013e3181cee1ea) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Progression-free survival (PFS) curves (A) and overall survival (OS) curves (B) for the group of never-smoker females with adenocarcinoma (N-F-A) and for the other groups among patients with advanced non-small cell lung cancer (NSCLC) with a poor performance status (PS) who were treated with first-line gefitinib. Survival difference was tested using the log-rank test. Journal of Thoracic Oncology 2010 5, 361-368DOI: (10.1097/JTO.0b013e3181cee1ea) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions